These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 23223768)

  • 61. Treatment of mycosis fungoides/Sezary syndrome: the University of California, San Francisco (UCSF) approach.
    Zackheim HS
    Int J Dermatol; 2003 Jan; 42(1):53-6. PubMed ID: 12581145
    [No Abstract]   [Full Text] [Related]  

  • 62. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
    Olsen EA; Rook AH; Zic J; Kim Y; Porcu P; Querfeld C; Wood G; Demierre MF; Pittelkow M; Wilson LD; Pinter-Brown L; Advani R; Parker S; Kim EJ; Junkins-Hopkins JM; Foss F; Cacchio P; Duvic M
    J Am Acad Dermatol; 2011 Feb; 64(2):352-404. PubMed ID: 21145619
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A retrospective study of prognostic factors and treatment outcome in advanced-stage Mycosis Fungoides and Sezary Syndrome.
    Xu ZF; Chen H; Liu Y; Zhang W; Jin H; Liu J
    Hematology; 2024 Dec; 29(1):2366631. PubMed ID: 38975808
    [No Abstract]   [Full Text] [Related]  

  • 64. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
    Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
    J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mycosis fungoides and sezary syndrome: an update.
    Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
    Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
    Wong HK
    Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
    Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
    J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
    Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
    Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
    Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
    Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
    [TBL] [Abstract][Full Text] [Related]  

  • 70. How I treat mycosis fungoides and Sézary syndrome.
    Whittaker S; Hoppe R; Prince HM
    Blood; 2016 Jun; 127(25):3142-53. PubMed ID: 27151889
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants.
    Slater DN
    Br J Dermatol; 2005 Nov; 153(5):874-80. PubMed ID: 16225594
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical roundtable monograph. The management of aggressive T-cell lymphoma: a discussion on transformed mycosis fungoides.
    Horwitz SM; Duvic M; Hsi ED
    Clin Adv Hematol Oncol; 2010 Dec; 8(12):1-15. PubMed ID: 21344783
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Does the new staging system proposed for mycosis fungoides and Sézary syndrome provide reliable agreement for T1 and T2 disease?
    Fernández-de-Misa R; Hernández Machín B; Aguirre-Jaime A; Pérez-Méndez LI; Peñate Y; Suárez Hernández J
    Dermatology; 2015; 230(1):40-5. PubMed ID: 25471055
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epidermal Langerhans cells in mycosis fungoides and Sézary syndrome.
    Matejka M; Konrad K
    Wien Klin Wochenschr; 1983 Dec; 95(23):847-52. PubMed ID: 6670281
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mycosis fungoides and the Sézary syndrome.
    Gisselbrecht C; Dubertret L
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):73-5. PubMed ID: 8511044
    [No Abstract]   [Full Text] [Related]  

  • 78. Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome.
    Jothishankar B; Almazan T; Kim Y; Liauw S; Smith S; Kline J; Abdulla F
    Br J Haematol; 2019 Jul; 186(2):377-379. PubMed ID: 30937886
    [No Abstract]   [Full Text] [Related]  

  • 79. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
    Berg S; Villasenor-Park J; Haun P; Kim EJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Treatment of mycosis fungoides and Sézary syndrome].
    Nicolay JP; Assaf C
    Hautarzt; 2017 Sep; 68(9):702-710. PubMed ID: 28770285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.